Darwin Global Management as of March 31, 2024
Portfolio Holdings for Darwin Global Management
Darwin Global Management holds 12 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Vaxcyte (PCVX) | 25.0 | $188M | 2.8M | 68.31 | |
| Nuvalent Inc-a (NUVL) | 14.4 | $108M | 1.4M | 75.09 | |
| Keros Therapeutics (KROS) | 12.7 | $95M | 1.4M | 66.20 | |
| Biohaven (BHVN) | 10.8 | $81M | 1.5M | 54.69 | |
| Alpine Immune Sciences | 10.5 | $79M | 2.0M | 39.64 | |
| Beam Therapeutics (BEAM) | 9.3 | $70M | 2.1M | 33.04 | |
| Apogee Therapeutics (APGE) | 7.4 | $55M | 832k | 66.45 | |
| Xencor (XNCR) | 3.3 | $25M | 1.1M | 22.13 | |
| Spyre Therapeutics Com New (SYRE) | 2.4 | $18M | 473k | 37.93 | |
| Elevation Oncology (ELEV) | 1.6 | $12M | 2.3M | 5.13 | |
| Tourmaline Bio (TRML) | 1.4 | $11M | 465k | 22.90 | |
| Merck & Co (MRK) | 1.4 | $11M | 80k | 131.95 |
